Last reviewed · How we verify

Shady Grove Fertility Reproductive Science Center — Portfolio Competitive Intelligence Brief

Shady Grove Fertility Reproductive Science Center pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Progesterone in Oil (PIO) Only Progesterone in Oil (PIO) Only marketed Progestin; Hormone replacement Progesterone receptor (PR) Reproductive/Fertility

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Shady Grove Fertility Reproductive Science Center:

Cite this brief

Drug Landscape (2026). Shady Grove Fertility Reproductive Science Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shady-grove-fertility-reproductive-science-center. Accessed 2026-05-17.

Related